Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | The mechanism of ibrutinib in CLL treatment

Francesco Forconi • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Francesco Forconi, MD, PhD, University of Southampton, Southampton, UK, discusses the mechnisms by which ibrutinib works on B-cell receptor (BCR) signalling in chronic lymphocytic leukemia (CLL) treatment and how we might find alternative targets. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Francesco Forconi

3:48
Using BTK degraders as a treatment strategy for patients with CLL
Francesco Forconi • 5 Oct 2023
3:24
Currently available approaches for treating CLL
Francesco Forconi • 5 Oct 2023
2:31
Treatment considerations for IgHV-unmutated and mutated CLL
Francesco Forconi • 4 Apr 2022
2:01
Novel combination therapies for the treatment of CLL
Francesco Forconi • 4 Apr 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals